CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Statistics

Total Valuation

CRSP has a market cap or net worth of $4.39 billion. The enterprise value is $2.61 billion.

Market Cap	4.39B
Enterprise Value	2.61B

Important Dates

The next estimated earnings date is Monday, November 4, 2024, after market close.

Earnings Date	Nov 4, 2024
Ex-Dividend Date	n/a

Share Statistics

CRSP has 88.52 million shares outstanding. The number of shares has increased by 3.72% in one year.

Shares Outstanding	88.52M
Shares Change (YoY)	+3.72%
Shares Change (QoQ)	+3.82%
Owned by Insiders (%)	0.45%
Owned by Institutions (%)	65.68%
Float	87.07M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	19.97
Forward PS	30.98
PB Ratio	2.13
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	12.90
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 15.73, with a Debt / Equity ratio of 0.12.

Current Ratio	15.73
Quick Ratio	15.66
Debt / Equity	0.12
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -14.00% and return on invested capital (ROIC) is -10.37%.

Return on Equity (ROE)	-14.00%
Return on Assets (ROA)	-9.77%
Return on Capital (ROIC)	-10.37%
Revenue Per Employee	$496,872
Profits Per Employee	-$653,081
Employee Count	407
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

In the past 12 months, CRSP has paid $2.66 million in taxes.

Income Tax	2.66M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +4.09% in the last 52 weeks. The beta is 1.67, so CRSP's price volatility has been higher than the market average.

Beta (5Y)	1.67
52-Week Price Change	+4.09%
50-Day Moving Average	50.94
200-Day Moving Average	60.86
Relative Strength Index (RSI)	54.81
Average Volume (20 Days)	978,634

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CRSP had revenue of $202.23 million and -$265.80 million in losses. Loss per share was -$3.27.

Revenue	202.23M
Gross Profit	-282.47M
Operating Income	-354.68M
Pretax Income	-263.15M
Net Income	-265.80M
EBITDA	-335.17M
EBIT	-354.68M
Loss Per Share	-$3.27

Balance Sheet

The company has $2.00 billion in cash and $231.30 million in debt, giving a net cash position of $1.78 billion or $20.13 per share.

Cash & Cash Equivalents	2.00B
Total Debt	231.30M
Net Cash	1.78B
Net Cash Per Share	$20.13
Equity (Book Value)	1.98B
Book Value Per Share	23.29
Working Capital	1.88B

Cash Flow

In the last 12 months, operating cash flow was -$121.76 million and capital expenditures -$4.28 million, giving a free cash flow of -$126.04 million.

Operating Cash Flow	-121.76M
Capital Expenditures	-4.28M
Free Cash Flow	-126.04M
FCF Per Share	-$1.42

Margins

Gross margin is -139.68%, with operating and profit margins of -175.39% and -131.44%.

Gross Margin	-139.68%
Operating Margin	-175.39%
Pretax Margin	-130.13%
Profit Margin	-131.44%
EBITDA Margin	-165.74%
EBIT Margin	-175.39%
FCF Margin	-62.33%

Dividends & Yields

CRSP does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.72%
Shareholder Yield	-3.72%
Earnings Yield	-6.06%
FCF Yield	-2.87%

Analyst Forecast

The average price target for CRSP is $74.38, which is 49.99% higher than the current price. The consensus rating is "Buy".

Price Target	$74.38
Price Target Difference	49.99%
Analyst Consensus	Buy
Analyst Count	19
Revenue Growth Forecast (5Y)	42.09%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CRSP has an Altman Z-Score of 7.82 and a Piotroski F-Score of 4.

Altman Z-Score	7.82
Piotroski F-Score	4